BioSpace News Archive

— FDA RMAT Designation for RP-L201 to Help Expedite Development and Registration — — Enrollment Complete in Phase 1/2 Clinical Trial of RP-L201 for the Treatment of LAD-I —

Paige, a global leader in AI-based diagnostic software in pathology, announced that KKR, a leading global investment firm, joined Casdin Capital and Johnson & Johnson Innovation – JJDC, Inc. as co-leads in its Series C financing round, bringing the round to over $125 million.

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 33 rd Annual Roth Conference.

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET

Initiative seeks to create interventions to prevent kidney failure and improve access to kidney disease research, care for communities of color

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will be presenting at four upcoming healthcare conferences.

Coverage for novel formulation of duloxetine now offered to 91% of lives in top 10 Medicare Part D plans Broader access to Drizalma Sprinkle™ reinforces Sun Pharma’s commitment to the 40% of American adults who cannot or will not swallow solid medication forms

– First patient dosed in the multiple ascending dose portion of Phase 1/2a MONARCH study of STK-001 in Dravet syndrome – – Preliminary safety and PK data from the single ascending dose portion of MONARCH still expected in H2 2021 – – As of December 31, 2020, Company had $287.5 million in cash, cash equivalents and restricted cash, anticipated to fund operations into 2024 –

Stratasys Ltd. introduced a new 3D printer that gives dental labs 3D printing efficiency paired with PolyJet’s realism and precision.

Visus Therapeutics Inc. today announced the close of a $36 million Series A Preferred Stock financing. Johnson & Johnson Innovation - JJDC, Inc. (JJDC), RTW Investments, LP, and Wille AG participated in the round, with additional participation from the Company’s existing shareholders